Abstract:Background PSS is a kind of autoimmune disease without clear pathogenesis. Treg cell plays an important role in autoimmune disease. However, opinions about change of amount of Treg cells in peripheral blood in autoimmune disease are various. Besides, the researches mainly focus on RA and SLE but not PSS. Objectives To explore the change of the number of Th17 and Treg (CD4+CD25+Foxp3+T cells) cells in peripheral blood in PSS and the effects of low dose IL-2 therapy on the balance of Treg and Th17 cells. Methods One hundred and ninety two PSS patients in our department, and 30 healthy controls were put in the research. The amount of Th17 cells and Treg cells were calculated by flow cytometry. Eighty eight in 192 were given low-dose IL-2 (50 WIU/day for 5 days) by hypodermic injection combined with standard therapy which includes glucocorticoid, immune-suppressants, biological agents or combination of them, while others (12 in 69) were given standard therapy only. The amount of these cells were calculated again after therapy. Results There was significant decrease in the absolute number of Treg cells and significant increase of the ratio of Th17/Treg cells in PSS patients when compared with healthy controls. There was no significant difference in absolute number of Th17 cells between PSS patients and healthy controls. Further, the number of Treg cells were negatively relative to ESSDAI. Traditional DMARDs had no obvious impact on Treg and Th17 cells. The amount of Treg cells significantly increased after the treatment of IL-2 by 1 week. But there was no significant improvement in clinical manifestations in the short time when comparing combinational treatment of IL-2 and classical drugs with classical therapy. No obvious adverse reactions were observed.Table 1. Absolute number and percentage of CD4+T subsets in peripheral blood in PSS patients and Healthy controls. Study Participants Health PSS Untreated PSS Th17 6.44 (5.10, 8.55) 7.09 (4.05, 11.48) 6.08 (4.30, 12.60) Treg 36.20 (27.82, 47.02) 28.24 (15.89, 41.36)* 27.30 (17.43, 39.87)* Th17% 0.96 (0.67, 1.33) 1.26 (0.77, 1.95)* 1.26 (0.86, 1.92)^ Treg% 4.80 (4.19, 6.37) 4.64 (3.10, 6.44) 4.70 (2.52, 6.91) Th17/Treg 0.18 (0.14, 0.29) 0.27 (0.15, 0.43)* 0.28 (0.15, 0.47)^ Median (range, cells/μl). ^P<0.1, *p<0.05, **p<0.01, ***p<0.0001 vs Healthy controls.Figure 1 Conclusions The number of CD4+CD25+Foxp3+T cells in peripheral blood was decreased obviously and was inversely related to ESSDAI. While there was no significant difference of Th17 cells between PSS patients and healthy controls. And there was no correlation between the number of Th17 cells and ESSDAI. So the imbalance of Th17/Treg is due to the decrease of Treg cells not increase of Th17 cell which indicates that the pathogenesis of PSS maybe mainly because of shortage of autoimmune tolerance. Low dose IL-2 therapy can effectively promote proliferation of Treg cells by which low dose IL-2 may induce and restore autoimmune tolerance to benefit disease control. References Takayoshi Morita et al. The Proportion of Regulatory T Cells in Patients with Rheumatoid Arthritis: A Meta-Analysis. PLoS One. 2016 Sep 13. Noack, M. & Miossec, P. Th17 and regulatory T cell balance in autoimmune and inflammatory diseases. Autoimmun Rev. 13, 668–677 (2014). Disclosure of Interest None declared

Frequency and significance of CD4~+CD25~+CD127~(low/-) T cells in the peripheral blood of patients with primary Sjgren's syndrome

Follicular Helper T Cells and Follicular Regulatory T Cells in the Immunopathology of Primary Sjögren's Syndrome

Follicular helper T cells and follicular regulatory T cells in the immunopathology of primary Sjogren's syndrome

[Expression of CD4+ CD25+ Regulatory T Cells in Peripheral Blood and Salivary Gland of Patients with Primary Sjögren's Syndrome].

[Clinical Significance of CD4+CD25+ T Cells in Peripheral Blood of Patients in Systemic Lupus Erythematosus].

Tph Cells Expanded in Primary Sjögren’s Syndrome

T Regulatory Cells Are Markedly Diminished in Diseased Salivary Glands of Patients with Primary Sjögren's Syndrome.

Expression of FcγRⅡb on peripheral B cells and its clinical significance in patients with primary Sj(o)gren's syndrome

SAT0252 the Number of Treg Cells in Peripheral Blood in Pss Patients is Decreased and Low Dose IL-2 Can Promote Its Proliferation

FRI0450 Associations of alterations of peripheral regulatory t and th17 absolute cell numbers with clinical features in patients with systemic sclerosis

Elevated Level of Circulating CD4+Helios+FoxP3+ Cells in Primary Sjogren's Syndrome Patients.

Expression and role of CD4+CD25+CD127low/-T cells of the peripheral blood in rheumatoid arthritis patients

DIFFERENTIAL EXPRESSION OF PERIPHERAL CD4+T CELLS IN PATIENTS WITH SYSTEMIC SCLEROSIS AND MIXED CONNECTIVE TISSUE DISEASE

THU0412 Absolute reduction of peripheral cd4 + regulatory t cell subset of patients with systemic sclerosis and its restoration by short-term and low dose il-2 treatment

[Expression of CD4+ CD25+ CD127(low/-) T Cells in Patients with Systemic Lupus Erythematosus].

Foxp3 expression in CD4~+CD25~+CD127~(low/-) regulatory T cells and its immunosuppressive effect in patients with systemic lupus erythematosus

Alteration of CD226/TIGIT immune checkpoint on T cells in the pathogenesis of primary Sjögren's syndrome

Involvement of expanded cytotoxic and proinflammatory CD28null T cells in primary Sjögren's syndrome

The Clinical Relevance of IL-17-Producing CD4+CD161+ Cell and Its Subpopulations in Primary Sjögren's Syndrome

CD4+CXCR5+ Follicular Helper T Cells in Salivary Gland Promote B Cells Maturation in Patients with Primary Sjogren's Syndrome.

The role of imbalanced CD226/TIGIT on activated peripheral double-negative T cells in the pathogenesis of primary Sjögren's syndrome